Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Tr1x | 2025 | Venture - Series Unknown | $50.0M | San Diego |
| AeroRx Therapeutics | 2025 | Series A | $21.0M | La Jolla |
| Dualitas Therapeutics | 2025 | Series A | $65.0M | San Francisco |
| Leal Therapeutics | 2025 | Series A | $30.0M | Worcester |
| GeneCentric Therapeutics | 2025 | Series C | $8.0M | Durham |
| Remedy Plan Therapeutics | 2025 | Venture - Series Unknown | $18.0M | Gaithersburg |
| Hoofprint Biome | 2025 | Series A | $15.0M | Raleigh |
| Garuda Therapeutics | 2025 | Series A | $50.0M | Cambridge |
| Ten63 Therapeutics | 2024 | Series A | Undisclosed | Durham |
| Pleno | 2024 | Series B | $25.0M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Tr1x | Venture - Series Unknown | $50.0M | San Diego, United States |
| 27 | AeroRx Therapeutics | Series A | $21.0M | La Jolla, United States |
| 28 | Dualitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 29 | Leal Therapeutics | Series A | $30.0M | Worcester, United States |
| 30 | GeneCentric Therapeutics | Series C | $8.0M | Durham, United States |
| 31 | Remedy Plan Therapeutics | Venture - Series Unknown | $18.0M | Gaithersburg, United States |
| 32 | Hoofprint Biome | Series A | $15.0M | Raleigh, United States |
| 33 | Garuda Therapeutics | Series A | $50.0M | Cambridge, United States |
| 34 | Ten63 Therapeutics | Series A | Undisclosed | Durham, United States |
| 35 | Pleno | Series B | $25.0M | San Diego, United States |
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Leal Therapeutics develops novel therapeutics for patients.
GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Hoofprint Biome is a biotechnology company that develops probiotics that improve the sustainability of ruminant livestock production.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world's most lethal diseases.
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
CrossBridge Bio operates as a biotechnology company.
Archon is a biotechnology firm that promotes next-generation antibody treatments through AI and computational protein design.
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs).
5Metis is a new pure-play discovery company for crop health.
Early stage biotechnology company
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Epic Sciences is a diagnostics company improving cancer management by providing real-time biopsy material to guide personalized medicine.
Melonfrost is a biotechnology company based in Brooklyn, New York.
Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.
Inari is a seed design and biotechnology company developing seeds for a nature-positive food system.
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 25 different industry categories.
Among tracked funding rounds, TRex Bio received $84.0M in a Series B round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Recent Alexandria Venture Investments portfolio additions include Tr1x, AeroRx Therapeutics, Dualitas Therapeutics, Leal Therapeutics, GeneCentric Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors